Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Moxifloxacin IV/PO for Treating Adult Subjects With Community-acquired Bacterial Pneumonia (CABP)

NCT06162286 is registered in ClinicalTrials.gov with Zai Lab (Hong Kong), Ltd. as lead sponsor.

NCT NCT06162286
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06162286 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Moxifloxacin IV/PO for Treating Adult Subjects With Community-acquired Bacterial Pneumonia (CABP)
Lead sponsor
Zai Lab (Hong Kong), Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
November 17, 2023
Completion date
November 30, 2025
Enrollment
100 (estimated)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

community-acquired bacterial pneumonia